Cargando…
Assessing the Future of Solid Tumor Immunotherapy
With the advent of cancer immunotherapy, there has been a major improvement in patient’s quality of life and survival. The growth of cancer immunotherapy has dramatically changed our understanding of the basics of cancer biology and has altered the standards of care (surgery, radiotherapy, and chemo...
Autores principales: | Guha, Prajna, Heatherton, Kara R., O’Connell, Kyle P., Alexander, Ian S., Katz, Steven C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945484/ https://www.ncbi.nlm.nih.gov/pubmed/35327456 http://dx.doi.org/10.3390/biomedicines10030655 |
Ejemplares similares
-
Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition
por: Ghosh, Chandra C., et al.
Publicado: (2022) -
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity
por: Chai, Louis F., et al.
Publicado: (2021) -
Advances in Cancer Immunotherapy in Solid Tumors
por: Menon, Smitha, et al.
Publicado: (2016) -
Recent updates on Sintilimab in solid tumor immunotherapy
por: Liu, Xuhong, et al.
Publicado: (2020) -
TCR engineered T cells for solid tumor immunotherapy
por: Zhang, Yikai, et al.
Publicado: (2022)